A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.

Midori Shima,Kagehiro Amano,Yoshiyuki Ogawa,Koichiro Yoneyama,Ryoto Ozaki,Ryota Kobayashi,Emiko Sakaida,Makoto Saito,Takashi Okamura,Toshihiro Ito,Norimichi Hattori,Satoshi Higasa,Nobuaki Suzuki,Yoshinobu Seki,Keiji Nogami

Journal of thrombosis and haemostasis : JTH（2023）

引用 11|浏览15

暂无评分

摘要

These results suggest that emicizumab prophylaxis with the tested dosing regimen and completion criteria may have a favorable benefit-risk profile in PwAHA.

查看译文

关键词

bispecific monoclonal antibodies,emicizumab,factor VIII deficiency, acquired,prophylaxis,prospective studies

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要